Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4934134 | 0.97 | CNR2 (0.94) | CNR2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL14007484 | 0.92 | CNR2 (0.86) | CNR2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4935227 | 0.92 | CNR2 (0.86) | CNR2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4934379 | 0.89 | CNR2 (1.00) | CNR2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4931244 | 0.87 | CNR2 (1.00) | CNR2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5214933 | 0.87 | CNR2 (0.82) | CNR2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4923355 | 0.86 | CNR2 (1.00) | CNR2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4929806 | 0.86 | CNR2 (0.93) | CNR2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4924214 | 0.85 | CNR2 (0.77) | CNR2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4923736 | 0.85 | CNR2 (0.74) | CNR2CYP2D6CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280952-A1 | Pyridine Derivatives as Connabinoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280952-A1 | Pyridine Derivatives as Connabinoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280952-A1 | Pyridine Derivatives as Connabinoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1735301-A1 | PYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005075464-A1 | PYRIDINE DERIVATIVES AS CONNABINOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280952-A1 | Pyridine Derivatives as Connabinoid Receptor Modulators | CNR1, CNR2, P2RY1 | CNR2 2/4885CYP2D6 1087/4885CYP2C9 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.